Jason A Gencher1, Nathaniel M Hawkins1,2, Marc W Deyell1,2, Jason G Andrade3,4,5. 1. University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada. 2. Center for Cardiovascular Innovation, Vancouver, Canada. 3. University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada. Jason.andrade@vch.ca. 4. Center for Cardiovascular Innovation, Vancouver, Canada. Jason.andrade@vch.ca. 5. Montreal Heart Institute, Université de Montréal, Montreal, Canada. Jason.andrade@vch.ca.
Abstract
PURPOSE OF REVIEW: Atrial fibrillation (AF) and heart failure (HF) are commonly encountered clinical disorders that often co-exist, accelerating disease progression and adverse outcomes. It is known that restoration of sinus rhythm positively impacts this population; however, the complex comorbidity profile associated with HF introduces intricacies not encountered in other patient populations. The current review focuses on the safety and efficacy of an interventional-based management for atrial tachyarrhythmias in HF. RECENT FINDINGS: While pharmacotherapy has been the standard treatment of cardiac dysrhythmias in the HF population, recent evidence suggests catheter ablation is more effective and causes less harm than antiarrhythmic drugs (AADs) in the HF population. For the maintenance of sinus rhythm, catheter ablation results in improved freedom from recurrent arrhythmia, with secondary benefit on mortality and hospitalization in those with HF and reduced ejection fraction. For those with permanent AF, cardiac resynchronization therapy and atrioventricular junction ablation result in improved quality of life, physical functioning, and cardiac function.
PURPOSE OF REVIEW: Atrial fibrillation (AF) and heart failure (HF) are commonly encountered clinical disorders that often co-exist, accelerating disease progression and adverse outcomes. It is known that restoration of sinus rhythm positively impacts this population; however, the complex comorbidity profile associated with HF introduces intricacies not encountered in other patient populations. The current review focuses on the safety and efficacy of an interventional-based management for atrial tachyarrhythmias in HF. RECENT FINDINGS: While pharmacotherapy has been the standard treatment of cardiac dysrhythmias in the HF population, recent evidence suggests catheter ablation is more effective and causes less harm than antiarrhythmic drugs (AADs) in the HF population. For the maintenance of sinus rhythm, catheter ablation results in improved freedom from recurrent arrhythmia, with secondary benefit on mortality and hospitalization in those with HF and reduced ejection fraction. For those with permanent AF, cardiac resynchronization therapy and atrioventricular junction ablation result in improved quality of life, physical functioning, and cardiac function.
Authors: Michael R MacDonald; Derek T Connelly; Nathaniel M Hawkins; Tracey Steedman; John Payne; Morag Shaw; Martin Denvir; Sai Bhagra; Sandy Small; William Martin; John J V McMurray; Mark C Petrie Journal: Heart Date: 2010-11-04 Impact factor: 5.994
Authors: Ulrik M Mogensen; Pardeep S Jhund; William T Abraham; Akshay S Desai; Kenneth Dickstein; Milton Packer; Jean L Rouleau; Scott D Solomon; Karl Swedberg; Michael R Zile; Lars Køber; John J V McMurray Journal: J Am Coll Cardiol Date: 2017-11-14 Impact factor: 24.094
Authors: Ross J Hunter; Thomas J Berriman; Ihab Diab; Ravindu Kamdar; Laura Richmond; Victoria Baker; Farai Goromonzi; Vinit Sawhney; Edward Duncan; Stephen P Page; Waqas Ullah; Beth Unsworth; Jamil Mayet; Mehul Dhinoja; Mark J Earley; Simon Sporton; Richard J Schilling Journal: Circ Arrhythm Electrophysiol Date: 2014-01-01
Authors: Akram Y Elgendy; Ahmed N Mahmoud; Muhammad S Khan; Maryam R Sheikh; Mohammad K Mojadidi; Mohamed Omer; Islam Y Elgendy; Anthony A Bavry; Kenneth A Ellenbogen; William M Miles; Matthew McKillop Journal: Am J Cardiol Date: 2018-06-05 Impact factor: 2.778
Authors: Luigi Di Biase; Prasant Mohanty; Sanghamitra Mohanty; Pasquale Santangeli; Chintan Trivedi; Dhanunjaya Lakkireddy; Madhu Reddy; Pierre Jais; Sakis Themistoclakis; Antonio Dello Russo; Michela Casella; Gemma Pelargonio; Maria Lucia Narducci; Robert Schweikert; Petr Neuzil; Javier Sanchez; Rodney Horton; Salwa Beheiry; Richard Hongo; Steven Hao; Antonio Rossillo; Giovanni Forleo; Claudio Tondo; J David Burkhardt; Michel Haissaguerre; Andrea Natale Journal: Circulation Date: 2016-03-30 Impact factor: 29.690
Authors: Mohammed N Khan; Pierre Jaïs; Jennifer Cummings; Luigi Di Biase; Prashanthan Sanders; David O Martin; Josef Kautzner; Steven Hao; Sakis Themistoclakis; Raffaele Fanelli; Domenico Potenza; Raimondo Massaro; Oussama Wazni; Robert Schweikert; Walid Saliba; Paul Wang; Amin Al-Ahmad; Salwa Beheiry; Pietro Santarelli; Randall C Starling; Antonio Dello Russo; Gemma Pelargonio; Johannes Brachmann; Volker Schibgilla; Aldo Bonso; Michela Casella; Antonio Raviele; Michel Haïssaguerre; Andrea Natale Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: Omar M Aldaas; Florentino Lupercio; Douglas Darden; Praneet S Mylavarapu; Chaitanya L Malladi; Frederick T Han; Kurt S Hoffmayer; David Krummen; Gordon Ho; Farshad Raissi; Ulrika Birgersdotter-Green; Gregory K Feld; Jonathan C Hsu Journal: Am J Cardiol Date: 2020-12-05 Impact factor: 2.778